- Condition: Multiple Myeloma
Interventions: Drug: Placebo; Drug: Dexamethasone; Drug: Bortezomib; Biological: Tabalumab
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Not yet recruiting - verified May 2012 - Condition: Breast Cancer
Intervention:
Sponsors: Genentech; Genentech; 23andMe, Inc.
Recruiting - verified May 2012 - Condition: Head and Neck Cancer
Interventions: Drug: MEHD7945A; Drug: cetuximab
Sponsors: Genentech; Genentech
Not yet recruiting - verified April 2012 - Conditions: Brain and Central Nervous System Tumors; Neurofibromatosis Type 1
Intervention: Drug: lenalidomide
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Melanoma
Interventions: Biological: POL-103A; Biological: POL-103A without API
Sponsors: Polynoma LLC; Polynoma LLC
Recruiting - verified May 2012 - Condition: Vertebral Metastasis
Interventions: Radiation: Stereotactic Radiation Therapy; Radiation: SRT with Vertebral Augmentation Procedure
Sponsors: James Graham Brown Cancer Center; Shiao Woo, MD
Recruiting - verified March 2012 - Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: erlotinib; Drug: afatinib
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Conditions: Primary Peritoneal Carcinoma; Ovarian Carcinoma; Fallopian Tube Carcinoma
Intervention: Drug: neoadjuvant chemotherapy
Sponsors: University of Kentucky; University of Kentucky
Recruiting - verified May 2012 - Condition: Endometrial Cancer
Intervention: Procedure: Lymphadenectomy
Sponsors: University of Kentucky; University of Kentucky
Recruiting - verified December 2011 - Conditions: Head and Neck Cancer; Kidney Cancer; Liver Cancer; Sarcoma
Interventions: Drug: sorafenib tosylate; Genetic: gene expression analysis; Genetic: mutation analysis; Genetic: polymerase chain reaction; Other: enzyme-linked immunosorbent assay; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Locally Recurrent Breast Cancer; Metastatic Breast Cancer
Interventions: Drug: NKTR-102; Drug: Treatment of Physician's Choice (TPC)
Sponsors: Nektar Therapeutics; Nektar Therapeutics
Recruiting - verified April 2012 - Condition: Lung Cancer
Intervention: Radiation: 4D-CT pre-treatment scan
Sponsors: James Graham Brown Cancer Center; Neal Dunlap, MD
Recruiting - verified January 2012 - Condition: Melanoma
Interventions: Biological: BMS-982470 (recombinant interleukin-21); Biological: BMS-982470 (recombinant interleukin-21); Biological: BMS-982470 (recombinant interleukin-21); Biological: BMS-982470 (recombinant interleukin-21); Biological: Ipilimumab; Biological: Ipilimumab; Biological: Ipilimumab
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified February 2012 - Condition: Squamous Cell Carcinoma
Intervention:
Sponsors: University of Louisville; University of Louisville
Recruiting - verified June 2011 - Condition: HER2 Negative Breast Cancer
Interventions: Biological: NeuVax vaccine; Biological: Leukine (sargramostim, GM-CSF) and water for injection
Sponsors: Galena Biopharma, Inc.; Galena Biopharma, Inc.
Recruiting - verified May 2012 - Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung CancerCondition: Lung Cancer - Non Small Cell
Interventions: Biological: Ipilimumab; Biological: Pemetrexed
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Not yet recruiting - verified February 2012 - Condition: Pancreatic Cancer
Interventions: Drug: GS-6624; Drug: GS-6624; Drug: Placebo; Drug: Gemcitabine; Drug: Gemcitabine; Drug: Gemcitabine; Drug: Gemcitabine; Drug: GS-6624
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified March 2012 - Condition: Colorectal Cancer
Interventions: Drug: GS-6624; Drug: FOLFIRI; Drug: GS-6624; Drug: FOLFIRI; Drug: GS-6624; Drug: FOLFIRI; Drug: Placebo; Drug: FOLFIRI
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified March 2012 - Condition: Follicular Lymphoma
Interventions: Drug: Rituximab; Drug: Lenalidomide; Drug: Rituximab-CHOP; Drug: Rituximab-CVP; Drug: Rituximab-Bendamustine
Sponsors: Celgene Corporation; Celgene Corporation; Groupe d'Etude des Lymphomes de l'Adulte - Recherche Clinique
Recruiting - verified April 2012 - Condition: Multiple Myeloma
Interventions: Biological: Elotuzumab; Drug: Bortezomib; Drug: Dexamethasone; Drug: Dexamethasone; Drug: Dexamethasone; Drug: Dexamethasone
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Abbott Biotherapeutics Corp.
Recruiting - verified February 2012 - Condition: Brain and Central Nervous System Tumors
Interventions: Drug: sunitinib malate; Genetic: gene expression analysis; Genetic: protein expression analysis; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Non-Small Cell Lung Cancer
Interventions: Drug: onartuzumab [MetMAb]; Drug: erlotinib [Tarceva]; Drug: Placebo
Sponsors: Genentech; Genentech; Hoffmann-La Roche
Recruiting - verified January 2012 - Condition: Leukemia, Pediatric
Intervention: Drug: Dasatinib
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Children's Oncology Group; EsPhALL - European Intergroup Study on Post Induction Treatment of Philadelphia Positive Acute Lymphoblastic Leukaemia with Imatinib
Recruiting - verified April 2012 - Condition: Endometrial Carcinoma
Intervention: Drug: GDC-0980
Sponsors: Genentech; Genentech
Recruiting - verified October 2011 - Condition: Small Cell Lung Carcinoma
Interventions: Biological: Ipilimumab; Biological: Placebo matching Ipilimumab; Drug: Etoposide; Drug: Cisplatin; Drug: Carboplatin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified October 2011 - Condition: Myelodysplastic Syndrome
Interventions: Drug: Siltuximab + BSC; Drug: Placebo + BSC
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified April 2012 - Condition: Non-Small Cell Lung Cancer
Intervention:
Sponsors: Precision Therapeutics; Precision Therapeutics
Recruiting - verified January 2012 - Condition: Hematopoietic Neoplasm
Interventions: Drug: SAR302503; Drug: Placebo
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Non-small Cell Lung Cancer
Intervention: Dietary Supplement: Blueberry powder
Sponsors: James Graham Brown Cancer Center; James Graham Brown Cancer Center
Recruiting - verified August 2011 - Condition: Hematopoietic Neoplasm
Intervention: Drug: SAR302503
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Lymphoma, B-Cell
Interventions: Drug: RO50722759; Drug: cyclophosphamide; Drug: doxorubicin; Drug: vincristine; Drug: prednisone
Sponsors: Genentech; Genentech
Recruiting - verified May 2012 - Condition: Lymphocytic Leukemia, Chronic
Interventions: Drug: RO5072759; Drug: RO5072759
Sponsors: Genentech; Genentech
Recruiting - verified November 2011 - Condition: Lymphoma
Interventions: Biological: rituximab; Drug: bendamustine hydrochloride; Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: leucovorin calcium; Drug: methotrexate; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Metastatic Breast Cancer
Interventions: Drug: eribulin mesylate; Drug: eribulin mesylate; Drug: eribulin mesylate, trastuzumab
Sponsors: Sarah Cannon Research Institute; Sarah Cannon Research Institute; Eisai Inc.
Recruiting - verified March 2012 - Conditions: Cognitive/Functional Effects; Leukemia; Neurotoxicity; Pain; Therapy-related Toxicity
Interventions: Drug: clofarabine; Drug: cyclophosphamide; Drug: cytarabine; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: hydrocortisone sodium succinate; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: thioguanine; Drug: vincristine sulfate; Radiation: selective external radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Lymphoma
Intervention: Drug: SAR245409
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Unresectable Stage III or IV Melanoma
Interventions: Biological: INXN-2001; Drug: INXN-1001
Sponsors: ZIOPHARM; ZIOPHARM
Recruiting - verified April 2012 - Conditions: Cachexia; Non-Small Cell Lung Cancer
Interventions: Drug: Anamorelin HCl; Drug: Placebo
Sponsors: Helsinn Therapeutics (U.S.), Inc; Helsinn Therapeutics (U.S.), Inc
Recruiting - verified May 2012 - Conditions: Cachexia; Non-Small Cell Lung Cancer
Interventions: Drug: Anamorelin HCl; Drug: Placebo
Sponsors: Helsinn Therapeutics (U.S.), Inc; Helsinn Therapeutics (U.S.), Inc
Recruiting - verified May 2012 - Conditions: Arthralgia; Breast Cancer; Pain
Interventions: Dietary Supplement: omega-3 fatty acid; Other: placebo
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Metastatic ER+ Her2- Breast Cancer; Postmenopausal
Interventions: Drug: Exemestane; Drug: Abiraterone acetate + Prednisone/ Prednisolone + Exemestane; Drug: Abiraterone acetate + Prednisone or Prednisolone
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified May 2012 - Condition: Acute Myeloid Leukemia
Intervention:
Sponsors: Center for International Blood and Marrow Transplant Research; Center for International Blood and Marrow Transplant Research; Resource for Clinical Investigations in Blood and Marrow Transplantation (RCI-BMT); Pediatric Blood and Marrow Transplant Consortium
Recruiting - verified May 2012 - Condition: Prostate Cancer
Interventions: Radiation: radiation therapy; Radiation: selective external radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Leukemia
Interventions: Drug: asparaginase; Drug: bortezomib; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: etoposide; Drug: mitoxantrone hydrochloride; Drug: sorafenib tosylate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Biological: filgrastim; Drug: carboplatin; Drug: paclitaxel; Other: pharmacological study; Other: questionnaire administration; Procedure: assessment of therapy complications; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group
Recruiting - verified May 2012 - Conditions: Crohn's Disease; IBD; Colitis; Inflammatory Bowel Disease
Interventions: Drug: Group 2 ustekinumab 130 mg; Drug: Group 3: ustekinumab approximately 6 mg/kg; Drug: Group 1: Placebo
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified April 2012 - Conditions: Bacterial Infection; Leukemia; Musculoskeletal Complications; Neutropenia
Interventions: Drug: levofloxacin; Procedure: standard follow-up care
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Hematologic Neoplasms
Intervention:
Sponsors: Center for International Blood and Marrow Transplant Research; Center for International Blood and Marrow Transplant Research; National Marrow Donor Program
Recruiting - verified June 2011 - Conditions: Pain; Advanced Cancer
Interventions: Drug: Sativex®; Drug: Placebo (GA-0034)
Sponsors: GW Pharmaceuticals Ltd.; GW Pharmaceuticals Ltd.; Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified August 2011 - Condition: Small Cell Lung Carcinoma
Intervention: Drug: Amuvatinib
Sponsors: Astex Pharmaceuticals; Astex Pharmaceuticals
Recruiting - verified May 2012 - Conditions: Muscle Wasting; Non Small Cell Lung Cancer
Interventions: Drug: GTx-024; Drug: placebo
Sponsors: GTx; GTx; Harrison Clinical Research
Recruiting - verified May 2012 - Conditions: Muscle Wasting; Non-Small Cell Lung Cancer
Interventions: Drug: GTx-024; Drug: placebo
Sponsors: GTx; GTx; Harrison Clinical Research
Recruiting - verified May 2012 - Condition: Non-Small Cell Lung Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: Standard of care treatment
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2012 - Conditions: Hematological Malignancies; Certain Lysosomal Storage and Peroxisomal Enzyme Deficiency Disorders; Hurler Syndrome (MPS I); Krabbe Disease (Globoid Leukodystrophy); X-linked Adrenoleukodystrophy; Primary Immunodeficiency Diseases; Bone Marrow Failure; Beta-thalassemia
Intervention: Drug: A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
Sponsors: Center for International Blood and Marrow Transplant Research; Center for International Blood and Marrow Transplant Research; National Marrow Donor Program
Recruiting - verified April 2012 - Condition: Breast Cancer
Interventions: Radiation: 3-dimensional conformal radiation therapy; Radiation: accelerated radiation therapy; Radiation: hypofractionated radiation therapy; Radiation: intensity-modulated radiation therapy; Radiation: whole breast irradiation
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Cancer; Hematologic Malignancies; Multiple Myeloma; Oncology; Bone Metastases; Multiple Myeloma Bone Lesions
Interventions: Drug: Denosumab; Drug: Zoledronic acid
Sponsors: Amgen; Amgen; Daiichi Sankyo Inc.
Recruiting - verified May 2012 - Condition: Advanced Liposarcoma or Leiomyosarcoma
Interventions: Drug: Trabectedin; Drug: Dacarbazine
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC; Pharma Mar, S.A.U.
Recruiting - verified May 2012 - Condition: Lung Cancer
Interventions: Procedure: therapeutic conventional surgery; Radiation: iodine I 125; Radiation: stereotactic body radiation therapy
Sponsors: National Cancer Institute (NCI); American College of Surgeons; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Non-Small Cell Lung Cancer (NSCLC)
Interventions: Drug: Dacomitinib (PF-00299804); Drug: Active Comparator (erlotinib)
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Chemotherapy-Induced Nausea and Vomiting
Interventions: Drug: Netupitant and Palonosetron; Drug: Palonosetron
Sponsors: Helsinn Healthcare SA; Helsinn Healthcare SA; Parexel
Recruiting - verified December 2011 - Condition: Leukemia, Myelocytic, Acute
Interventions: Drug: Fludarabine and Busulfan (Flu/Bu); Drug: Fludarabine and Melphalan (Flu/Mel); Drug: Busulfan and Fludarabine (Bu/Flu); Drug: Busulfan and Cyclophosphamide (Bu/Cy); Drug: Cyclophosphamide and Total Body Irradiation (Cy/TBI)
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); National Heart, Lung, and Blood Institute (NHLBI); National Cancer Institute (NCI); Blood and Marrow Transplant Clinical Trials Network
Recruiting - verified March 2012 - Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide; Drug: Dexamethasone; Drug: Dexamethasone; Drug: Dexamethasone; Drug: Dexamethasone; Biological: Elotuzumab (BMS-901608; HuLuc63); Biological: Elotuzumab (BMS-901608; HuLuc63)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Abbott Biotherapeutics Corp.
Recruiting - verified October 2011 - Condition: Neuroblastoma
Interventions: Biological: hu14.18-IL2 fusion protein; Biological: sargramostim; Drug: isotretinoin; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Myeloma
Intervention: Drug: Simvastatin,Zoledronic Acid,Bortezomib,Bendamustine,Methylprednisolone.
Sponsors: James Graham Brown Cancer Center; Geoffry Herzig, MD
Recruiting - verified April 2012 - Conditions: Diffuse Large B-cell Lymphoma; de Novo DLBCL; DLBCL Transformed From Indolent Lymphoma; Follicular Grade 3 Lymphoma
Interventions: Drug: Pixantrone + Rituximab; Drug: Gemcitabine + Rituximab
Sponsors: Cell Therapeutics; Cell Therapeutics
Recruiting - verified May 2012 - Condition: Thyroid Cancer
Interventions: Drug: lenvatinib 24 mg administered orally, once a day; Drug: Placebo 24mg administered orally, once a day
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified April 2012 - Condition: Prostate Cancer
Interventions: Drug: abiraterone acetate; Drug: degarelix; Drug: goserelin acetate; Drug: leuprolide acetate; Procedure: orchiectomy
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Condition: Prostate Cancer
Interventions: Drug: Cabazitaxel (XRP6258); Drug: Docetaxel (XRP6976); Drug: Prednisone
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified April 2012 - Condition: Prostate Cancer
Interventions: Drug: Cabazitaxel (XRP6258); Drug: Prednisone
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Conditions: Advanced Prostate Cancer; Prostatic Neoplasms
Intervention: Biological: sipuleucel-T
Sponsors: Dendreon; Dendreon
Recruiting - verified March 2012 - Conditions: Head and Neck Cancer; Precancerous Condition
Interventions: Biological: cetuximab; Drug: cisplatin
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Fungal Infection; Leukemia; Neutropenia
Interventions: Drug: caspofungin acetate; Drug: fluconazole
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Non-small Cell Lung Cancer (NSCLC)
Intervention: Radiation: Stereotactic Body Radiation Therapy
Sponsors: James Graham Brown Cancer Center; James Graham Brown Cancer Center
Recruiting - verified June 2011 - Condition: Colorectal Cancer Metastatic
Interventions: Drug: Regorafenib (BAY 73-4506); Drug: FOLFIRI; Drug: Placebo; Drug: FOLFIRI
Sponsors: UNC Lineberger Comprehensive Cancer Center; UNC Lineberger Comprehensive Cancer Center; Bayer
Recruiting - verified April 2012 - Condition: Pancreatic Cancer
Interventions: Biological: ganitumab; Drug: capecitabine; Drug: gemcitabine hydrochloride; Radiation: 3-dimensional conformal radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Drug: TLR8 agonist VTX-2337; Drug: pegylated liposomal doxorubicin hydrochloride; Other: laboratory biomarker analysis; Other: pharmacogenomic studies; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Colorectal Cancer
Interventions: Biological: Imprime PGG + cetuximab; Drug: Cetuximab
Sponsors: Biothera; Biothera
Recruiting - verified April 2012 - Condition: Colon Cancer
Interventions: Dietary Supplement: curcumin; Dietary Supplement: Curcumin conjugated with plant exosomes; Other: No intervention
Sponsors: James Graham Brown Cancer Center; James Graham Brown Cancer Center
Recruiting - verified September 2011 - Condition: Lung Cancer, Small Cell
Interventions: Drug: pazopanib; Drug: pemetrexed
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012 - Condition: Lung Cancer - Non Small Cell
Interventions: Drug: Ipilimumab; Drug: Placebo; Drug: Paclitaxel; Drug: Carboplatin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified April 2012 - Condition: Breast Cancer
Intervention: Radiation: accelerated hypofractionated radiotherapy (AHF-RT)
Sponsors: James Graham Brown Cancer Center; James Graham Brown Cancer Center; University of Louisville
Recruiting - verified December 2011 - Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast CancerCondition: Breast Cancer
Interventions: Biological: trastuzumab; Drug: cyclophosphamide; Drug: docetaxel; Drug: doxorubicin hydrochloride; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified February 2012 - Condition: Glioblastoma Multiforme
Interventions: Biological: ICT-107; Biological: Placebo DC
Sponsors: ImmunoCellular Therapeutics, Ltd.; ImmunoCellular Therapeutics, Ltd.
Recruiting - verified May 2012 - Condition: Breast Cancer
Interventions: Drug: anastrozole; Drug: exemestane; Drug: letrozole; Drug: systemic chemotherapy; Drug: tamoxifen citrate
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Condition: Solid Organ Tumors
Intervention:
Sponsors: Precision Therapeutics; Precision Therapeutics
Recruiting - verified January 2012 - Condition: Metastatic Pancreatic Cancer
Interventions: Biological: bavituximab; Drug: Gemcitabine
Sponsors: Peregrine Pharmaceuticals; Peregrine Pharmaceuticals
Recruiting - verified May 2012 - Condition: Breast Cancer
Intervention: Drug: Eribulin Mesylate
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified March 2012 - Condition: Melanoma (Skin)
Interventions: Biological: ipilimumab; Biological: recombinant interferon alfa-2b
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Anemia; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small-Cell Lung; Bladder Cancer; Cancer of Head and Neck; Uterine Cervical Cancer
Interventions: Drug: ACE-011 - 15 mg; Drug: ACE-011 - 30 mg; Drug: ACE-011 - 45 mg
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified February 2012 - Condition: Herpes Zoster
Interventions: Biological: V212; Biological: Placebo
Sponsors: Merck; Merck
Recruiting - verified May 2012 - Condition: Breast Cancer
Interventions: Procedure: palliative surgery; Procedure: therapeutic conventional surgery; Radiation: palliative radiation therapy; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Prostate Cancer
Interventions: Behavioral: telephone-based intervention; Other: counseling intervention; Other: educational intervention; Procedure: therapeutic dietary intervention
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Condition: Chronic Myeloid Leukemia
Intervention:
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; ICON Clinical Research
Recruiting - verified May 2012 - Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide; Drug: Dexamethasone; Drug: Dexamethasone (Oral); Drug: Dexamethasone (IV); Biological: Elotuzumab (BMS-901608; HuLuc63)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Abbott Biotherapeutics Corp.
Recruiting - verified May 2012 - Condition: Non-small Cell Lung Cancer
Interventions: Drug: ISIS EIF4E Rx; Drug: ISIS EIF4E Rx; Drug: ISIS EIF4E Rx; Drug: Paclitaxel; Drug: Carboplatin
Sponsors: Isis Pharmaceuticals; Isis Pharmaceuticals
Recruiting - verified March 2012 - Condition: Castrate-Resistant Prostate Cancer
Interventions: Drug: ISIS EIF4E Rx; Drug: ISIS EIF4E Rx; Drug: ISIS EIF4E Rx; Drug: Prednisone; Drug: Docetaxel
Sponsors: Isis Pharmaceuticals; Isis Pharmaceuticals
Recruiting - verified April 2012 - Conditions: Brain and Central Nervous System Tumors; Kidney Cancer; Sarcoma
Interventions: Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: topotecan hydrochloride; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Metastatic Pancreatic Adenocarcinoma
Intervention: Drug: CO-1.01
Sponsors: Clovis Oncology, Inc.; Clovis Oncology, Inc.
Recruiting - verified March 2012 - Conditions: Lymphoma, Non-Hodgkin; Lymphoma, B-cell; Lymphoma, B-cell, Diffuse
Interventions: Drug: Inotuzumab ozogamicin; Drug: Rituximab; Drug: rituximab + gemcitabine; Drug: rituximab +bendamustine
Sponsors: Pfizer; Pfizer; UCB, Inc.
Recruiting - verified April 2012 - Condition: Head and Neck Cancer
Interventions: Drug: cisplatin; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Prostate Neoplasms; Genital Neoplasms, Male; Urogenital Neoplasms; Genital Diseases, Male
Intervention: Drug: Abiraterone Acetate
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Available - verified April 2012 - Condition: Brain and Central Nervous System Tumors
Interventions: Biological: bevacizumab; Drug: irinotecan hydrochloride; Drug: temozolomide
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Sarcoma
Interventions: Biological: bevacizumab; Drug: cyclophosphamide; Drug: temsirolimus; Drug: vinorelbine tartrate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Breast Cancer
Interventions: Drug: Sorafenib(Nexavar, BAY43-9006) / Capecitabine; Drug: Placebo / Capecitabine
Sponsors: Bayer; Bayer; Onyx Therapeutics, Inc.
Recruiting - verified April 2012 - Condition: Adenocarcinoma of the Lung
Interventions: Biological: farletuzumab; Other: Placebo; Drug: Platinum Containing Doublet
Sponsors: Morphotek; Morphotek
Recruiting - verified May 2012 - Condition: Prostate Cancer
Interventions: Drug: MDV3100; Drug: Placebo
Sponsors: Medivation, Inc.; Medivation, Inc.; Astellas Pharma Inc
Recruiting - verified February 2012 - Condition: Metastatic Renal Cell Carcinoma
Interventions: Drug: Dovitinib; Drug: Sorafenib
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Kidney Cancer
Interventions: Biological: bevacizumab; Drug: everolimus; Other: placebo
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Conditions: Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer
Interventions: Biological: trastuzumab; Drug: carboplatin; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Basal Cell Carcinoma
Interventions: Drug: vismodegib (GDC-0449); Drug: vismodegib (GDC-0449); Drug: vismodegib (GDC-0449)
Sponsors: Genentech; Genentech
Recruiting - verified May 2012 - Condition: Lymphoma, Follicular
Interventions: Biological: Ofatumumab; Biological: Rituximab
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012 - Conditions: Oral Squamous Cell Carcinoma; Oral Epithelial Dysplasia
Interventions: Drug: Bioadhesive 10% freeze-dried black raspberry gel; Drug: Color/consistency matched placebo gel
Sponsors: Ohio State University; Ohio State University; University of Louisville; University of North Carolina, Chapel Hill; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Condition: Leukemia
Interventions: Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: thioguanine; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Non Small Cell Lung Cancer
Interventions: Drug: Docetaxel; Biological: Ramucirumab; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company; ImClone LLC
Recruiting - verified May 2012 - Condition: Carcinoma, Squamous Cell of the Head and Neck
Interventions: Biological: REOLYSIN; Drug: Carboplatin; Drug: Paclitaxel; Drug: Placebo
Sponsors: Oncolytics Biotech; Oncolytics Biotech
Recruiting - verified March 2012 - Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Biological: 1121B (ramucirumab); Drug: Pemetrexed; Drug: Carboplatin (AUC 6); Drug: Cisplatin; Drug: Gemcitabine; Drug: Carboplatin (AUC 5)
Sponsors: ImClone LLC; ImClone LLC
Recruiting - verified December 2011 - Condition: Ovarian Cancer
Interventions: Drug: EC145; Drug: Pegylated Liposomal Doxorubicin (PLD/Doxil®/Caelyx®); Drug: placebo; Drug: EC20
Sponsors: Endocyte; Endocyte
Recruiting - verified March 2012 - Conditions: Brain and Central Nervous System Tumors; Childhood Germ Cell Tumor; Kidney Cancer; Leukemia; Liver Cancer; Neuroblastoma; Sarcoma
Interventions: Drug: alisertib; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Colorectal Cancer
Interventions: Drug: celecoxib; Drug: fluorouracil; Drug: leucovorin calcium; Drug: oxaliplatin; Other: placebo
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Conditions: Breast Cancer; Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Other: questionnaire administration; Procedure: evaluation of cancer risk factors; Procedure: quality-of-life assessment; Procedure: study of high risk factors
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Leukemia
Interventions: Genetic: DNA ploidy analysis; Genetic: chromosomal translocation analysis; Genetic: cytogenetic analysis; Genetic: fluorescence in situ hybridization; Other: cytology specimen collection procedure; Other: flow cytometry; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Hepatocellular Carcinoma
Interventions: Biological: Placebo; Biological: Ramucirumab DP (IMC-1121B)
Sponsors: ImClone LLC; ImClone LLC
Recruiting - verified February 2012 - Condition: Unresectable Stage III or Stage IV Melanoma
Interventions: Drug: E7080; Drug: E7080
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified January 2012 - Condition: Lymphoma
Interventions: Biological: bleomycin sulfate; Drug: ABVD regimen; Drug: BEACOPP regimen; Drug: cyclophosphamide; Drug: dacarbazine; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: prednisone; Drug: procarbazine hydrochloride; Drug: vinblastine sulfate; Drug: vincristine sulfate; Other: laboratory biomarker analysis; Procedure: computed tomography; Radiation: fludeoxyglucose F 18; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Stage IIIC Melanoma; Stage IV Melanoma
Intervention: Drug: Denileukin diftitox
Sponsors: Eisai Inc.; Eisai Inc.; PharmaBio Development Inc.
Recruiting - verified May 2012 - Condition: Kidney Cancer
Interventions: Drug: everolimus; Other: placebo
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Condition: Kidney Neoplasms
Intervention: Procedure: Cryoablation
Sponsors: Galil Medical; Galil Medical
Recruiting - verified October 2011 - Condition: Breast Cancer
Interventions: Drug: trastuzumab emtansine; Drug: pertuzumab; Drug: pertuzumab-placebo; Drug: trastuzumab [Herceptin]; Drug: docetaxel; Drug: paclitaxel
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche; Genentech
Recruiting - verified March 2012 - Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide; Drug: lenalidomide, bortezomib and dexamethasone; Drug: Lenalidomide
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); National Heart, Lung, and Blood Institute (NHLBI); Blood and Marrow Transplant Clinical Trials Network; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Condition: Breast Cancer
Interventions: Drug: metformin hydrochloride; Other: placebo
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Cervical Cancer
Interventions: Drug: cisplatin; Radiation: external beam radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Conditions: Colon Cancer; Rectal Cancer
Interventions: Biological: IMC-1121B; Biological: IMC-18F1; Drug: mFOLFOX-6
Sponsors: ImClone LLC; ImClone LLC
Recruiting - verified April 2012 - Conditions: brca1 Mutation Carrier; brca2 Mutation Carrier; Breast Cancer
Interventions: Dietary Supplement: cholecalciferol; Other: placebo
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Brain and Central Nervous System Tumors
Interventions: Drug: cisplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: vincristine sulfate; Other: clinical observation; Radiation: 3-dimensional conformal radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Squamous Cell Lung Cancer
Interventions: Drug: gemcitabine/carboplatin; Drug: gemcitabine/carboplatin plus Iniparib
Sponsors: Sanofi-Aventis; Sanofi-Aventis; BiPar Sciences
Recruiting - verified March 2012 - Conditions: Fallopian Tube Cancer; Ovarian Cancer
Interventions: Biological: bevacizumab; Drug: capecitabine; Drug: carboplatin; Drug: oxaliplatin; Drug: paclitaxel; Procedure: quality-of-life assessment
Sponsors: University College, London; University College, London; National Cancer Institute (NCI); Gynecologic Oncology Group
Recruiting - verified December 2011 - Condition: Multiple Myeloma
Intervention:
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified June 2011 - Condition: Pancreatic Cancer
Interventions: Biological: HyperAcute-Pancreas Immunotherapy; Drug: Gemcitabine; Radiation: 5FU Chemoradiation
Sponsors: NewLink Genetics Corporation; NewLink Genetics Corporation
Recruiting - verified May 2012 - Conditions: Non-Hodgkin's Lymphoma; Mantle Cell Lymphoma
Intervention: Drug: bendamustine and rituximab
Sponsors: Teva Pharmaceutical Industries; Cephalon
Recruiting - verified May 2012 - Condition: Breast Cancer
Interventions: Drug: Placebo; Drug: Denosumab
Sponsors: Amgen; Amgen; Daiichi Sankyo Inc.
Recruiting - verified May 2012 - Condition: Lung Cancer
Interventions: Radiation: prophylactic cranial irradiation; Radiation: selective external radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Sarcoma
Interventions: Biological: cixutumumab; Biological: dactinomycin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: irinotecan hydrochloride; Drug: temozolomide; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Ovarian Cancer
Interventions: Biological: bleomycin sulfate; Drug: carboplatin; Drug: cisplatin; Drug: etoposide phosphate; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Non-Small-Cell Lung Cancer
Interventions: Drug: Carboplatin; Drug: Pemetrexed; Drug: Panitumumab
Sponsors: Sarah Cannon Research Institute; Sarah Cannon Research Institute; Amgen
Recruiting - verified October 2011 - Condition: Lung Cancer
Interventions: Drug: carboplatin; Drug: celecoxib; Drug: gemcitabine hydrochloride; Drug: pemetrexed disodium; Other: placebo
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Conditions: Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Carcinoma
Interventions: Drug: Pazopanib; Drug: Doxil
Sponsors: Sarah Cannon Research Institute; Sarah Cannon Research Institute; GlaxoSmithKline
Recruiting - verified November 2011 - Condition: Metastatic Breast Cancer
Intervention: Drug: Amrubicin
Sponsors: Sarah Cannon Research Institute; Sarah Cannon Research Institute; Celgene Corporation
Recruiting - verified July 2011 - Condition: Lymphoma
Interventions: Drug: Bendamustine; Drug: Bortezomib; Drug: Rituximab
Sponsors: Sarah Cannon Research Institute; Sarah Cannon Research Institute; Millennium Pharmaceuticals, Inc.; Cephalon
Recruiting - verified July 2011 - Conditions: Pancreatic Cancer; Ductal Adrenocarcinoma; Exocrine Pancreatic Cancer
Intervention: Drug: PCI-27483
Sponsors: Pharmacyclics; Pharmacyclics
Recruiting - verified January 2012 - Condition: Liver Cancer
Interventions: Drug: doxorubicin hydrochloride; Drug: sorafenib tosylate
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified September 2011 - Condition: Pancreatic Cancer
Interventions: Drug: capecitabine; Drug: erlotinib hydrochloride; Drug: fluorouracil; Drug: gemcitabine hydrochloride; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Colorectal Cancer; Precancerous Condition
Interventions: Drug: rosuvastatin; Other: placebo
Sponsors: National Cancer Institute (NCI); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified February 2012 - Condition: Sarcoma
Interventions: Biological: bevacizumab; Biological: filgrastim; Biological: pegfilgrastim; Drug: docetaxel; Drug: gemcitabine hydrochloride; Other: placebo
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Breast Cancer
Interventions: Drug: Paclitaxel; Drug: Trastuzumab; Drug: Neratinib; Drug: Trastuzumab (post surgery); Drug: Doxorubicin; Drug: Cyclophosphamide
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Surgical Adjuvant Breast and Bowel Project (NSABP); Wyeth Pharmaceuticals, Inc., a Pfizer Company
Recruiting - verified February 2012 - Conditions: HER2/Neu Over-expressing Locally Advanced Breast Cancer; Metastatic Breast Cancer
Interventions: Drug: everolimus, vinorelbine, trastuzumab; Drug: Placebo + vinorelbine + trastuzumab
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Conditions: Lymphoma; Lymphoproliferative Disorder
Interventions: Other: biologic sample preservation procedure; Other: informational intervention
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Lymphoma, B-Cell
Interventions: Drug: Pralatrexate Injection; Dietary Supplement: Vitamin B12; Dietary Supplement: Folic Acid
Sponsors: Allos Therapeutics; Allos Therapeutics
Recruiting - verified October 2011 - Condition: Lung Cancer
Intervention: Drug: bendamustine hydrochloride
Sponsors: Vanderbilt-Ingram Cancer Center; Vanderbilt-Ingram Cancer Center; National Cancer Institute (NCI)
Recruiting - verified October 2011 - Condition: Liver Cancer
Interventions: Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: fluorouracil; Drug: irinotecan hydrochloride; Drug: vincristine sulfate; Procedure: liver transplantation; Procedure: therapeutic conventional surgery
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified November 2011 - Condition: Lung Cancer
Interventions: Biological: panitumumab; Drug: carboplatin; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Brain and Central Nervous System Tumors; Neurotoxicity
Interventions: Drug: temozolomide; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Endometrial Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: ixabepilone; Drug: paclitaxel; Drug: temsirolimus
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified July 2011 - Condition: Head and Neck Cancer
Interventions: Biological: cetuximab; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Ovarian Cancer; Sarcoma
Interventions: Drug: carboplatin; Drug: ifosfamide; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Leukemia
Interventions: Genetic: DNA analysis; Genetic: RNA analysis; Genetic: cytogenetic analysis; Genetic: fluorescence in situ hybridization; Genetic: gene expression analysis; Genetic: microarray analysis; Genetic: mutation analysis; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Other: flow cytometry; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified December 2011 - Condition: Venous Thromboembolism
Intervention: Drug: Fragmin
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified April 2012 - Condition: Advanced Non-Small Cell Lung Cancer
Interventions: Drug: Pemetrexed; Drug: Carboplatin; Drug: Paclitaxel; Biological: Bevacizumab
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012 - Condition: Lung Cancer
Interventions: Biological: bevacizumab; Biological: cetuximab; Drug: carboplatin; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Endometrial Cancer
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Conditions: Bladder Cancer; Prostate Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter; Urethral Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: gemcitabine hydrochloride; Drug: placebo administration
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified August 2011 - Condition: Prostate Cancer
Interventions: Drug: bicalutamide; Drug: buserelin; Drug: flutamide; Drug: goserelin acetate; Drug: leuprolide acetate; Drug: triptorelin; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Colon Cancer With Metastases to the Liver
Interventions: Device: LC bead loaded with Irinotecan; Drug: FOLFOX6 and Avastin
Sponsors: University of Louisville; University of Louisville; Biocompatibles UK Ltd
Recruiting - verified November 2011 - Conditions: Human Papillomavirus (HPV) Type 16/18 Infections; Cervical Neoplasia
Intervention: Procedure: Gynaecological follow-up
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified March 2012 - Conditions: Pain, Burning; Pain, Crushing; Pain, Migratory; Pain, Radiating; Pain, Splitting
Interventions: Drug: JNJ-42160443; Drug: Placebo
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified May 2012 - Conditions: Metastatic Cancer; Pain
Interventions: Radiation: external beam radiation therapy; Radiation: image-guided radiation therapy; Radiation: radiosurgery; Radiation: stereotactic body radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Brain and Central Nervous System Tumors
Intervention: Other: biologic sample preservation procedure
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Chordoma; Desmoid Tumor; Sarcoma
Interventions: Genetic: reverse transcriptase-polymerase chain reaction; Other: biologic sample preservation procedure; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Lymphoma, Non-Hodgkin
Intervention: Biological: Hematopoietic Stem Cell Transplant
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); National Heart, Lung, and Blood Institute (NHLBI); Blood and Marrow Transplant Clinical Trials Network; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Conditions: Cancer; Colon Cancer; Colorectal Cancer; Fever; Locally Advanced; Metastatic Colorectal Cancer; Neutropenia; Rectal Cancer
Interventions: Drug: Pegfilgrastim; Drug: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified January 2012 - Condition: Non Small Cell Lung Cancer
Interventions: Drug: Pemetrexed; Drug: Carboplatin
Sponsors: Sarah Cannon Research Institute; Sarah Cannon Research Institute; Eli Lilly and Company
Recruiting - verified March 2012 - Condition: B-Cell Chronic Lymphocytic Leukemia (B-CLL)
Interventions: Drug: Lenalidomide; Drug: Chlorambucil
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified September 2011 - Condition: Neuroblastoma
Interventions: Genetic: fluorescence in situ hybridization; Genetic: gene expression analysis; Genetic: nucleic acid amplification; Genetic: polymerase chain reaction; Genetic: reverse transcriptase-polymerase chain reaction; Other: cytology specimen collection procedure; Other: flow cytometry; Procedure: biopsy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Cancer
Interventions: Genetic: DNA analysis; Genetic: reverse transcriptase-polymerase chain reaction; Other: biologic sample preservation procedure; Other: flow cytometry; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Kidney Cancer; Nonneoplastic Condition
Interventions: Genetic: loss of heterozygosity analysis; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Other: immunohistochemistry staining method; Procedure: computed tomography; Procedure: magnetic resonance imaging
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Leukemia; Neoplasm of Uncertain Malignant Potential; Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Other: cytology specimen collection procedure
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Intervention: Other: diagnostic laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Cancer
Intervention: Other: biologic sample preservation procedure
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified December 2011 - Condition: Sarcoma
Interventions: Other: biologic sample preservation procedure; Other: medical chart review
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Metastatic Breast Cancer
Interventions: Drug: Panitumumab; Drug: Carboplatin; Drug: Gemcitabine
Sponsors: Sarah Cannon Research Institute; Sarah Cannon Research Institute; Amgen; Eli Lilly and Company
Recruiting - verified October 2011 - Condition: Sarcoma
Intervention: Other: biologic sample preservation procedure
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Leukemia; Lymphoma
Intervention: Other: biologic sample preservation procedure
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Lymphoma
Intervention: Other: biologic sample preservation procedure
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Breast Cancer
Interventions: Drug: Paclitaxel; Drug: Carboplatin; Drug: Sunitinib; Drug: Paclitaxel; Drug: Carboplatin; Drug: Sunitinib
Sponsors: Sarah Cannon Research Institute; Sarah Cannon Research Institute; Pfizer
Recruiting - verified March 2012 - Condition: Breast Cancer
Interventions: Drug: Everolimus; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Prostate Cancer
Interventions: Drug: Ipilimumab; Drug: Placebo
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified December 2011 - Condition: Leukemia
Interventions: Drug: arsenic trioxide; Drug: cytarabine; Drug: idarubicin; Drug: mercaptopurine; Drug: methotrexate; Drug: mitoxantrone hydrochloride; Drug: tretinoin; Genetic: cytogenetic analysis; Genetic: polymerase chain reaction; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Non-Small Cell Lung Cancer; Anemia; Cancer; Lung Cancer
Interventions: Drug: darbepoetin alfa 500 mcg Q3W; Drug: placebo
Sponsors: Amgen; Amgen
Recruiting - verified May 2012 - Condition: Colorectal Cancer
Interventions: Drug: NKTR-102; Drug: irinotecan
Sponsors: Nektar Therapeutics; Nektar Therapeutics
Recruiting - verified April 2012 - Condition: Non-small Cell Lung Cancer
Interventions: Radiation: CyberKnife Stereotactic Radiotherapy; Procedure: Surgery
Sponsors: Accuray Incorporated; Accuray Incorporated; M.D. Anderson Cancer Center
Recruiting - verified February 2012 - Condition: Breast Cancer
Interventions: Drug: trastuzumab emtansine; Drug: lapatinib; Drug: capecitabine [Xeloda]
Sponsors: Genentech; Genentech
Recruiting - verified April 2012 - Condition: Metastatic Breast Cancer
Interventions: Drug: Sorafenib and Ixabepilone; Drug: Sorafenib and Ixabepilone
Sponsors: Sarah Cannon Research Institute; Sarah Cannon Research Institute; Bayer; Bristol-Myers Squibb
Recruiting - verified October 2011 - Condition: Lymphoma
Interventions: Biological: bleomycin sulfate; Biological: filgrastim; Drug: ABVD regimen; Drug: BEACOPP regimen; Drug: cyclophosphamide; Drug: dacarbazine; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: prednisone; Drug: procarbazine hydrochloride; Drug: vinblastine sulfate; Drug: vincristine sulfate; Radiation: fludeoxyglucose F 18
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Conditions: Endometrial Cancer; Fatigue; Neurotoxicity
Interventions: Drug: carboplatin; Drug: paclitaxel; Radiation: brachytherapy; Radiation: intensity-modulated radiation therapy; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Condition: Cervical Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: paclitaxel; Drug: topotecan hydrochloride
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified December 2011 - Condition: Metastatic Colorectal Cancer
Interventions: Biological: cetuximab; Drug: 5-FU; Drug: oxaliplatin; Drug: leucovorin
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Surgical Adjuvant Breast and Bowel Project (NSABP); Bristol-Myers Squibb
Recruiting - verified March 2012 - Condition: Leukemia
Interventions: Biological: filgrastim; Biological: graft versus host disease prophylaxis/therapy; Drug: cyclophosphamide; Drug: cytarabine; Drug: dasatinib; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: leucovorin calcium; Drug: methotrexate; Drug: methylprednisolone; Drug: prednisone; Drug: vincristine sulfate; Genetic: cytogenetic analysis; Genetic: polymerase chain reaction; Other: flow cytometry; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Radiation: total-body irradiation
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Diffuse Large B-cell Lymphoma
Interventions: Drug: RAD001; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Conditions: Brain and Central Nervous System Tumors; Chemotherapeutic Agent Toxicity; Cognitive/Functional Effects; Neurotoxicity; Psychosocial Effects of Cancer and Its Treatment; Radiation Toxicity; Therapy-related Toxicity
Interventions: Other: questionnaire administration; Procedure: cognitive assessment; Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Carcinoid Syndrome
Interventions: Drug: Somatuline Depot (lanreotide); Drug: placebo
Sponsors: Ipsen; Ipsen
Recruiting - verified April 2012 - Condition: Breast Cancer
Interventions: Biological: trastuzumab; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Non-small Cell Lung Cancer
Interventions: Drug: Pemetrexed; Drug: Pemetrexed; Drug: Paclitaxel; Drug: Carboplatin; Biological: Bevacizumab; Biological: Bevacizumab
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012 - Conditions: Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer
Interventions: Biological: panitumumab; Drug: cisplatin; Drug: docetaxel; Procedure: neoadjuvant therapy; Procedure: therapeutic conventional surgery; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); American College of Surgeons; National Cancer Institute (NCI)
Recruiting - verified June 2011 - Condition: Lung Cancer
Intervention: Radiation: stereotactic body radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Pancreatic Cancer
Interventions: Drug: Kanglaite Injection plus gemcitabine; Drug: Gemcitabine
Sponsors: KangLaiTe USA; KangLaiTe USA
Recruiting - verified January 2012 - Conditions: Colorectal Cancer; Colorectal Carcinoma; Liver Metastases
Interventions: Drug: Systemic chemotherapy (FOLFOX); Device: SIR-Spheres yttrium-90 microspheres; Drug: Systemic chemotherapy (FOLFOX)
Sponsors: Sirtex Medical; Sirtex Medical
Recruiting - verified May 2012 - Conditions: Brain and Central Nervous System Tumors; Childhood Germ Cell Tumor; Extragonadal Germ Cell Tumor; Liver Cancer; Neuroblastoma; Ototoxicity; Ovarian Cancer; Sarcoma
Interventions: Drug: sodium thiosulfate; Procedure: examination
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Non Small Cell Lung Cancer
Interventions: Drug: Pemetrexed; Drug: Cisplatin; Drug: Etoposide; Drug: Cisplatin; Drug: Vinorelbine; Drug: Paclitaxel; Drug: Carboplatin; Radiation: Thoracic Radiation Therapy (TRT); Radiation: Thoracic Radiation Therapy (TRT)
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012 - Condition: Retinoblastoma
Interventions: Genetic: DNA ploidy analysis; Genetic: DNA stability analysis; Genetic: Southern blotting; Genetic: genetic linkage analysis; Genetic: loss of heterozygosity analysis; Genetic: mutation analysis; Genetic: polymorphism analysis; Genetic: reverse transcriptase-polymerase chain reaction; Other: environmental carcinogenesis study; Other: questionnaire administration; Other: study of socioeconomic and demographic variables; Procedure: evaluation of cancer risk factors; Procedure: mutation carrier screening
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Non Small Cell Lung Cancer
Intervention: Dietary Supplement: beta-glucan
Sponsors: James Graham Brown Cancer Center; James Graham Brown Cancer Center
Recruiting - verified June 2011 - Condition: Symptomatic Refractory Resistant Carcinoid Disease
Interventions: Drug: Pasireotide; Drug: Octreotide
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified March 2012 - Conditions: Lung Neoplasm; Carcinoma Non-small Cell Lung Cancer Stage IIIA; Carcinoma Non-small Cell Lung Cancer Stage IIIB; Carcinoma Non-small Cell Lung Cancer Stage IV
Interventions: Biological: Lucanix™; Other: Placebo Comparator
Sponsors: NovaRx Corporation; NovaRx Corporation
Recruiting - verified April 2012 - Condition: Esophageal Cancer
Interventions: Biological: cetuximab; Drug: cisplatin; Drug: paclitaxel; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Brain and Central Nervous System Tumors
Interventions: Biological: filgrastim; Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: etoposide phosphate; Drug: methotrexate; Drug: thiotepa; Drug: vincristine sulfate; Genetic: mutation analysis; Other: immunohistochemistry staining method; Procedure: autologous hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Radiation: 3-dimensional conformal radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: MDS; AML; Solid Tumors; Multiple Myeloma; Non-Hodgkin's Lymphoma; Hodgkin's Disease
Interventions: Drug: azacitidine; Drug: azacitidine; Drug: azacitidine; Drug: azacitidine; Drug: azacitidine; Drug: azacitidine; Drug: azacitidine
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified March 2012 - Condition: Non-small Cell Lung Cancer
Intervention: Radiation: CyberKnife Stereotactic Radiosurgery
Sponsors: Accuray Incorporated; Accuray Incorporated; University of Pittsburgh
Recruiting - verified February 2012 - Condition: Lung Cancer
Interventions: Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI); Radiation Therapy Oncology Group
Recruiting - verified May 2012 - Condition: Hepatocellular Carcinoma
Interventions: Drug: ThermoDox; Drug: 5% Dextrose Solution
Sponsors: Celsion; Celsion
Recruiting - verified June 2011 - Condition: Head and Neck Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: cisplatin; Drug: docetaxel; Drug: fluorouracil
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Condition: Breast Cancer
Interventions: Drug: RAD001; Drug: Fulvestrant
Sponsors: University of Kentucky; University of Kentucky; Novartis
Recruiting - verified December 2011 - Condition: Prostate Cancer
Interventions: Drug: bicalutamide; Drug: flutamide; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI); Cancer and Leukemia Group B
Recruiting - verified May 2012 - Condition: Leukemia
Interventions: Drug: cyclophosphamide; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: thioguanine; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI); Eastern Cooperative Oncology Group; Southwest Oncology Group
Recruiting - verified May 2012 - Condition: Leukemia
Interventions: Drug: asparaginase; Drug: cyclophosphamide; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: etoposide; Drug: lestaurtinib; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: methylprednisolone; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Retinoblastoma
Interventions: Biological: filgrastim; Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: thiotepa; Drug: vincristine sulfate; Procedure: autologous bone marrow transplantation; Procedure: autologous hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Metastatic Melanoma
Intervention: Drug: Proleukin and Dacarbazine
Sponsors: James Graham Brown Cancer Center; James Graham Brown Cancer Center
Recruiting - verified September 2011 - Condition: Lung Cancer
Interventions: Procedure: therapeutic thoracoscopy; Procedure: videothoracoscopy
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI); Radiation Therapy Oncology Group; American College of Surgeons; Southwest Oncology Group
Recruiting - verified April 2012 - Condition: Endometrial Cancer
Interventions: Drug: cisplatin; Radiation: brachytherapy; Radiation: external beam radiation therapy
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Ototoxicity; Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Procedure: management of therapy complications
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Leukemia; Lymphoma
Interventions: Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: nelarabine; Drug: pegaspargase; Drug: prednisone; Drug: thioguanine; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Brain and Central Nervous System Tumors
Interventions: Biological: filgrastim; Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: isotretinoin; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Kidney Cancer; Metastatic Cancer
Interventions: Biological: dactinomycin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: vincristine sulfate; Procedure: therapeutic conventional surgery; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Condition: Leukemia
Interventions: Biological: filgrastim; Drug: asparaginase; Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: etoposide phosphate; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Conditions: Breast Cancer; Cognitive/Functional Effects; Lung Cancer; Metastatic Cancer; Prostate Cancer
Interventions: Radiation: radiation therapy; Radiation: stereotactic radiosurgery
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI); American College of Surgeons; Eastern Cooperative Oncology Group; Radiation Therapy Oncology Group
Recruiting - verified July 2011 - Conditions: Breast Cancer; Lymphedema; Perioperative/Postoperative Complications
Interventions: Behavioral: exercise intervention; Other: educational intervention; Procedure: assessment of therapy complications; Procedure: complementary or alternative medicine procedure; Procedure: management of therapy complications; Procedure: quality-of-life assessment; Procedure: therapeutic conventional surgery
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Breast Cancer; Neoplasm Metastasis
Interventions: Other: Standard supportive care (packed RBC transfusion); Drug: epoetin alfa + packed RBC transfusion
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified May 2012 - Condition: Brain and Central Nervous System Tumors
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: leucovorin calcium; Drug: methotrexate; Drug: thiotepa; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2011 - Condition: Lung Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: docetaxel; Drug: gemcitabine hydrochloride; Drug: pemetrexed disodium; Drug: vinorelbine tartrate
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI); Southwest Oncology Group; Cancer and Leukemia Group B; NCIC Clinical Trials Group; North Central Cancer Treatment Group
Recruiting - verified February 2012 - Condition: Breast Cancer
Intervention: Drug: Zometa® (zoledronic acid)
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Prostate Cancer
Interventions: Drug: antiandrogen therapy; Drug: docetaxel
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Condition: Adrenocortical Carcinoma
Interventions: Biological: filgrastim; Biological: pegfilgrastim; Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: mitotane; Procedure: conventional surgery
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified July 2011 - Condition: Melanoma
Interventions: Procedure: Completion Lymphadenectomy; Procedure: Monitoring with nodal ultrasound
Sponsors: John Wayne Cancer Institute; John Wayne Cancer Institute; National Institutes of Health (NIH)
Recruiting - verified January 2012 - Condition: Sarcoma
Intervention: Drug: Trabectedin
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified May 2012 - Condition: Prostate Cancer
Interventions: Drug: Docetaxel; Drug: Prednisone
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs; Sanofi-Aventis
Recruiting - verified September 2011 - Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With OsteosarcomaCondition: Sarcoma
Interventions: Biological: PEG-interferon alfa-2b; Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: methotrexate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI); University College London Hospitals
Recruiting - verified June 2011 - Condition: Breast Cancer
Interventions: Radiation: 3-dimensional conformal accelerated partial breast irradiation; Radiation: brachytherapy; Radiation: whole breast irradiation
Sponsors: National Cancer Institute (NCI); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI); Radiation Therapy Oncology Group; Southwest Oncology Group
Recruiting - verified May 2012 - Condition: Neuroblastoma
Interventions: Biological: aldesleukin; Biological: monoclonal antibody Ch14.18; Biological: sargramostim; Drug: isotretinoin
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Sarcoma
Interventions: Biological: dactinomycin; Drug: busulfan; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: melphalan; Drug: vincristine sulfate; Procedure: autologous hematopoietic stem cell transplantation; Procedure: conventional surgery; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); University Hospitals, Leicester; National Cancer Institute (NCI); Children's Cancer and Leukaemia Group; Societe Francaise Oncologie Pediatrique; European Organization for Research and Treatment of Cancer - EORTC; Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany; Gesellschaft fur Padiatrische Onkologie und Hamatologie - Austria; Swiss Group for Clinical Cancer Research; EBMT Solid Tumors Working Party; Children's Oncology Group
Recruiting - verified December 2011 - Condition: Ovarian Cancer
Intervention: Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
 |
Join Clinical Trials in Kentucky for Cancer |
